Literature DB >> 15332419

Research methodology: cancer cachexia syndrome.

Max Dahele1, K C H Fearon.   

Abstract

Cachexia is a syndrome and therefore does not have a specific definition. Patients are characterized by the presence of anorexia, early satiety, weight loss, weakness, anaemia and oedema. These features occur to a variable extent in different patients and may change in severity during the course of a patient's illness. The multifactorial origin of cachexia precludes a uniform pathophysiological definition. Taken together these factors have hindered clinical studies both at a fundamental level and in terms of the introduction of effective therapy. The advent of novel therapeutic targets (e.g., ubiquitin-proteasome pathway) and biological response modifiers has opened possibilities for new clinical trials in cachexia. Regulatory authorities feel it is important not only to demonstrate efficacy in terms of patients' nutritional status (e.g., lean body mass) but also functional status (e.g., performance status). This article reviews current methods to assess the latter. Methods focused on measuring physical activity level (e.g., doubly labelled water technique or physical activity meters) promise objective data which can be readily interpreted in terms of clinically meaningful benefit.

Entities:  

Mesh:

Year:  2004        PMID: 15332419     DOI: 10.1191/0269216304pm906ra

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  8 in total

1.  Cachexia in pancreatic cancer: new treatment options and measures of success.

Authors:  Kenneth C H Fearon; Vickie E Baracos
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

2.  Skeletal muscle function during the progression of cancer cachexia in the male ApcMin/+ mouse.

Authors:  Brandon N VanderVeen; Justin P Hardee; Dennis K Fix; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2017-11-09

3.  Effects of exercise intervention on persons with metastatic cancer: a systematic review.

Authors:  Rebekah Beaton; Wendy Pagdin-Friesen; Christa Robertson; Cathy Vigar; Heather Watson; Susan R Harris
Journal:  Physiother Can       Date:  2009-07-16       Impact factor: 1.037

4.  Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study.

Authors:  Matthew Maddocks; Anthony Byrne; Colin D Johnson; Richard H Wilson; Kenneth C H Fearon; Andrew Wilcock
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

Review 5.  Thalidomide for managing cancer cachexia.

Authors:  Joanne Reid; Moyra Mills; Marie Cantwell; Chris R Cardwell; Liam J Murray; Michael Donnelly
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

6.  Cancer cachexia: mechanisms and clinical implications.

Authors:  Claire L Donohoe; Aoife M Ryan; John V Reynolds
Journal:  Gastroenterol Res Pract       Date:  2011-06-13       Impact factor: 2.260

7.  Functional, physiological and subjective responses to concurrent neuromuscular electrical stimulation (NMES) exercise in adult cancer survivors: a controlled prospective study.

Authors:  Dominic O'Connor; Olive Lennon; Matilde Mora Fernandez; Gabriel Ruiz Signorelli; Brian Caulfield
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

8.  Self-directed home-based neuromuscular electrical stimulation (NMES) in patients with advanced cancer and poor performance status: a feasibility study.

Authors:  Dominic O'Connor; Olive Lennon; Sarah Wright; Brian Caulfield
Journal:  Support Care Cancer       Date:  2020-03-16       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.